Document Detail

Recurrent rearrangements in prostate cancer: causes and therapeutic potential.
MedLine Citation:
PMID:  23410129     Owner:  NLM     Status:  MEDLINE    
DNA damage and genetic rearrangements are hallmarks of cancer. However, gene fusions as driver mutations in cancer have classically been a distinction in leukemia and other rare instances until recently with the discovery of gene fusion events occurring in 50 to 75% of prostate cancer patients. The discovery of the TMPRSS2-ERG fusion sparked an onslaught of discovery and innovation resulting in a delineation of prostate cancer via a molecular signature of gene fusion events. The increased commonality of high-throughput sequencing data coupled with improved bioinformatics approaches not only elucidated the molecular underpinnings of prostate cancer progression, but the mechanisms of gene fusion biogenesis. Interestingly, the androgen receptor (AR), already known to play a significant role in prostate cancer tumorigenesis, has recently been implicated in the processes resulting in gene fusions by inducing the spatial proximity of genes involved in rearrangements, promoting the formation of double-strand DNA breaks (DSB), and facilitating the recruitment of proteins for non-homologous end-joining (NHEJ). Our increased understanding of the mechanisms inducing genomic instability may lead to improved diagnostic and therapeutic strategies. To date, the majority of prostate cancer patients can be molecularly stratified based on their gene fusion status thereby increasing the potential for tailoring more specific and effective therapies.
Nicole M White; Felix Y Feng; Christopher A Maher
Related Documents :
18020799 - Justice as a dependent variable: subordinate charisma as a predictor of interpersonal a...
23550209 - The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery a...
16427759 - The dutch cancer information helpline: more critical patients after 10 years.
20889279 - Internet use leads cancer patients to be active health care consumers.
17255059 - Community support, community values:the experiences of lesbians diagnosed with cancer.
24096489 - Eya4 is inactivated biallelically at a high frequency in sporadic lung cancer and is as...
21497359 - Haplotype analysis of prostate stem cell antigen and association with prostate cancer r...
11254869 - The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of...
23462369 - Caffeic acid phenethyl ester as an adjuvant therapy for advanced prostate cancer.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current drug targets     Volume:  14     ISSN:  1873-5592     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-04-09     Completed Date:  2014-01-30     Revised Date:  2014-04-02    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  450-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
DNA Breaks, Double-Stranded
Gene Fusion
Gene Rearrangement*
Oncogene Proteins, Fusion / genetics,  metabolism
Prostatic Neoplasms / genetics*,  pathology*
Receptors, Androgen / genetics*,  metabolism
Grant Support
R00 CA149182/CA/NCI NIH HHS; R00 CA149182/CA/NCI NIH HHS
Reg. No./Substance:
0/Oncogene Proteins, Fusion; 0/Receptors, Androgen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression.
Next Document:  Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmen...